---
category: news
title: "BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer's Disease"
excerpt: "Studies designed to maximize BXCL501 opportunity to treat full spectrum of agitation, with an estimated 100 million agitation episodes in Alzheimer’s patients occurring in the U.S. annually No FDA approved therapies for treatment of agitation associated with Alzheimer’s NEW HAVEN,"
publishedDateTime: 2021-12-15T12:06:00Z
originalUrl: "https://www.tmcnet.com/usubmit/2021/12/15/9511632.htm"
webUrl: "https://www.tmcnet.com/usubmit/2021/12/15/9511632.htm"
type: article
quality: 0
heat: 0
published: false

provider:
  name: TMCnet
  domain: tmcnet.com

topics:
  - AI in Healthcare
  - AI

secured: "ufyQJQiI0S+EZy2o7xuVH6EWFotklvRe3RIMR61BDpyrP7n4qKza96kiMekDlUrnZdk5RAPd1pX14KRTpyeEDCK/B/tqmWYPuGQjN9XyKKSDblfX78NUtjLmjcuaTU6tZZTrcpdEa/xL4N7Qh4VALV8C3qDtP9jVAXGZw6dH4eq5quiz0Jkz5Cg0IT7C1xs+MljBGmN86xyts3K1j5QQlo5FCp3jhIQ5xnCfWgTL+dsiniRZkLumElHdl6i/1y0se/fwI7qewpOPaZVxK0W9B1Ptuf5puUWgmBU4xAjDaa44CvDwjTQme7uPxfyId2TctKFWmOuPwIS2VOQR6DCXBL2unIT7KahusI/QYN0xpaI=;HQ1zeXi/Yv+VXdxOZtBA6A=="
---

